Common side effects include headache, constipation, sleepiness, and dizziness.[4][5] Severe side effects may include blood clots,
psychosis, and
heart failure.[5] It is believed to work by acting on
NMDA receptors, working as pore blockers of these ion channels.[4]
Memantine was approved for medical use in the United States in 2003.[4] It is available as a
generic medication.[5] In 2021, it was the 170th most commonly prescribed medication in the United States, with more than 3million prescriptions.[6][7]
Medical use
Alzheimer's disease and dementia
Memantine is used to treat moderate-to-severe Alzheimer's disease, especially for people who are intolerant of or have a contraindication to
AChE (acetylcholinesterase)inhibitors.[8][9] One guideline recommends memantine or an AChE inhibitor be considered in people in the early-to-mid stage of dementia.[10]
Memantine has been associated with a modest improvement;[11] with small positive effects on
cognition, mood, behavior, and the ability to perform daily activities in moderate-to-severe Alzheimer's disease.[12][13] There does not appear to be any benefit in mild disease.[14]
Memantine when added to
donepezil in those with moderate-to-severe dementia resulted in "limited improvements" in a 2017 review.[15] The UK
National Institute for Clinical Excellence (NICE) issued guidance in 2018 recommending consideration of the combination of memantine with donepezil in those with moderate-to-severe dementia.[16]
Psychiatry
Bipolar disorder
Memantine has been investigated as a possible augmentation strategy for depression in
bipolar disorder but meta-analytic evidence does not support its clinical utility.[17]
Memantine has been recommended for use by professional organization consensus to prevent neurocognitive decline after
whole brain radiotherapy.[20]
Adverse effects
Memantine is, in general, well tolerated.[11] Common
adverse drug reactions (≥1% of people) include confusion, dizziness, drowsiness, headache, insomnia, agitation, and/or hallucinations. Less common adverse effects include vomiting, anxiety,
hypertonia,
cystitis, and increased
libido.[11][21]
Like many other
NMDA antagonists, memantine behaves as a
dissociative anesthetic at supratherapeutic doses.[22] Despite isolated reports, recreational use of memantine is rare due to the drug's long duration and limited availability.[22] Additionally, memantine seems to lack effects such as euphoria or hallucinations.[23]
Memantine is a low-affinity voltage-dependent
uncompetitiveantagonist at glutamatergic NMDA receptors.[26][27] By binding to the NMDA receptor with a higher affinity than
Mg2+ ions, memantine is able to inhibit the prolonged influx of
Ca2+ ions, particularly from extrasynaptic receptors, which forms the basis of neuronal excitotoxicity. The low affinity, uncompetitive nature, and rapid off-rate kinetics of memantine at the level of the NMDA receptor-channel, however, preserves the function of the receptor at synapses, as it can still be activated by physiological release of
glutamate following
depolarization of the
postsynaptic neuron.[28][29][30] The interaction of memantine with NMDA receptors plays a major role in the symptomatic improvement that the drug produces in Alzheimer's disease. However, there is no evidence as yet that the ability of memantine to protect against extrasynaptic NMDA receptor-mediated excitotoxicity has a disease-modifying effect in Alzheimer's, although this has been suggested in animal models.[29]
Memantine's antagonism on NMDA receptors has aroused interest in repurposing it for mental illnesses such as
bipolar disorder,[17] considering the involvement of the glutamatergic system in the pathophysiology of mood disorders.[31]
Serotonin
Memantine acts as a non-competitive antagonist at the
5-HT3 receptor, with a potency similar to that for the NMDA receptor.[32] Many 5-HT3 antagonists function as
antiemetics, however the clinical significance of this
serotonergic activity in the treatment of Alzheimer's disease is unknown.
Cholinergic
Memantine acts as a non-competitive antagonist at different neuronal
nicotinic acetylcholine receptors (nAChRs) at potencies possibly similar to the NMDA and 5-HT3 receptors, but this is difficult to ascertain with accuracy because of the rapid desensitization of nAChR responses in these experiments. It can be noted that memantine is an antagonist at
Alpha-7 nAChR, which may contribute to initial worsening of cognitive function during early memantine treatment.
Alpha-7 nAChRupregulates quickly in response to antagonism, which could explain the cognitive-enhancing effects of chronic memantine treatment.[33][34] It has been shown that the number of
nicotinic receptors in the brain are reduced in Alzheimer's disease, even in the absence of a general decrease in the number of neurons, and
nicotinic receptoragonists are viewed as interesting targets for anti-Alzheimer drugs.[35]
Dopamine
Memantine was shown in a study[36] to act as an agonist at the dopamine
D2HIGH receptor with equal or slightly higher affinity than to the NMDA receptors; however, the relevance of this may be negligible, as studies have shown very low affinity for binding to D2 receptors in general.[37]
Sigmaergic
Memantine acts as an agonist at the
σ1 receptor with a low affinity (Ki 2.6
μM).[38] The consequences of this activity are unclear (as the role of sigma receptors in general is currently not very well understood). Due to this low affinity, therapeutic concentrations of memantine are most likely too low to have any
sigmaergic effect as a typical therapeutic dose is 20 mg. However, excessive doses of memantine taken for recreational purposes many times greater than prescribed doses may indeed activate this receptor.[39]
Memantine was first synthesized and patented by Eli Lilly and Company in 1968 as an anti-diabetic agent, but it was ineffective at lowering blood sugar. Later it was discovered to have
central nervous system (CNS) activity, and was developed by
Merz for dementia in Germany; the NMDA activity was discovered after trials had already begun. Memantine was first marketed for dementia in Germany in 1989 under the name Axura.[40]
In the US, some CNS activities were discovered at
Children's Hospital of Boston in 1990, and Children's licensed patents covering uses of memantine outside the field of ophthalmology to
Neurobiological Technologies (NTI) in 1995.[41] In 1998 NTI amended its agreement with Children's to allow Merz to take over development.[42]
In 2000, Merz partnered with
Forest to develop the drug for Alzheimer's disease in the U.S. under the name Namenda.[40]
In 2000, Merz partnered with Suntory for the Japanese market and with Lundbeck for other markets including Europe;[43] the drug was originally marketed by Lundbeck under the name Ebixa.[40]
Sales of the drug reached $1.8 billion for 2014.[44] The cost of Namenda was $269 to $489 a month in 2012.[45]
In February 2014, as the July 2015 patent expiration for memantine neared,
Actavis, which had acquired Forest, announced that it was launching an extended release (XR) form of memantine that could be taken once a day instead of twice a day as needed with the then-current "immediate release" (IR) version, and that it intended to stop selling the IR version in August 2014 and withdraw the marketing authorization. This is a tactic to thwart generic competition called
product hopping. However the supply of the XR version ran short, so Actavis extended the deadline until the fall. In September 2014 the attorney general of New York,
Eric Schneiderman, filed a lawsuit to compel Actavis to keep selling the IR version on the basis of
antitrust law.[46][47]
In December 2014, a judge granted New York State its request and issued an injunction, preventing Actavis from withdrawing the IR version until generic versions could launch. Actavis appealed and in May a panel of the
Second Circuit Court of Appeals upheld the injunction, and in June Actavis asked that its case be heard by the full Second Circuit panel.[48][49] In August 2015, Actavis' request was denied.[50]
Society and culture
Recreational use
One preclinical study on
monkeys showed that memantine was capable of inducing a
PCP-like
intoxication.[51] Because of its very long biological half-life, memantine was previously thought not to be recreational, although a few cases of sporadic recreational use have been described.[52]
A study examining self-reported use of memantine on the social network
Reddit showed that the drug was used recreationally and as a
nootropic, but also that it was misused in various illnesses as self-medication without strong scientific basis.[53]
Memantine, in light of its NMDA receptor antagonism, has been repurposed as a possible adjunctive treatment for depressive episodes in subjects with
bipolar disorder, considering the involvement of the glutamatergic system in the pathophysiology of bipolar illness.[31] However, evidence from meta-analyses showed that memantine was not significantly superior to placebo for bipolar depression.[17]
^van Dyck CH, Tariot PN, Meyers B, Malca Resnick E (2007). "A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease". Alzheimer Disease and Associated Disorders. 21 (2): 136–143.
doi:
10.1097/WAD.0b013e318065c495.
PMID17545739.
S2CID25621202.
^Schneider LS, Dagerman KS, Higgins JP, McShane R (August 2011). "Lack of evidence for the efficacy of memantine in mild Alzheimer disease". Archives of Neurology. 68 (8): 991–998.
doi:
10.1001/archneurol.2011.69.
PMID21482915.
S2CID18870666.
^
abcBartoli F, Cavaleri D, Bachi B, Moretti F, Riboldi I, Crocamo C, et al. (November 2021). "Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials". Journal of Psychiatric Research. 143: 230–238.
doi:
10.1016/j.jpsychires.2021.09.018.
PMID34509090.
S2CID237485915.
^
abMorris H, Wallach J (2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Testing and Analysis. 6 (7–8): 614–632.
doi:
10.1002/dta.1620.
PMID24678061.
^Swedberg MD, Ellgren M, Raboisson P (April 2014). "mGluR5 antagonist-induced psychoactive properties: MTEP drug discrimination, a pharmacologically selective non-NMDA effect with apparent lack of reinforcing properties". The Journal of Pharmacology and Experimental Therapeutics. 349 (1): 155–164.
doi:
10.1124/jpet.113.211185.
PMID24472725.
S2CID787751.
^
abParsons CG, Stöffler A, Danysz W (November 2007). "Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse". Neuropharmacology. 53 (6): 699–723.
doi:
10.1016/j.neuropharm.2007.07.013.
PMID17904591.
S2CID6599658.
^Lipton SA (October 2007). "Pathologically activated therapeutics for neuroprotection". Nature Reviews. Neuroscience. 8 (10): 803–808.
doi:
10.1038/nrn2229.
PMID17882256.
S2CID34931289.
^
abBartoli F, Misiak B, Callovini T, Cavaleri D, Cioni RM, Crocamo C, et al. (July 2021). "The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites". Molecular Psychiatry. 26 (7): 3419–3429.
doi:
10.1038/s41380-020-00913-1.
PMID33077852.
S2CID224314102.
^Rammes G, Rupprecht R, Ferrari U, Zieglgänsberger W, Parsons CG (June 2001). "The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner". Neuroscience Letters. 306 (1–2): 81–84.
doi:
10.1016/S0304-3940(01)01872-9.
PMID11403963.
S2CID9655208.
^Buisson B, Bertrand D (March 1998). "Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor". Molecular Pharmacology. 53 (3): 555–563.
doi:
10.1124/mol.53.3.555.
PMID9495824.
S2CID5865674.
^Aracava Y, Pereira EF, Maelicke A, Albuquerque EX (March 2005). "Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons". The Journal of Pharmacology and Experimental Therapeutics. 312 (3): 1195–1205.
doi:
10.1124/jpet.104.077172.
PMID15522999.
S2CID17585264.
^Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM, Hermans E (April 2004). "Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine". The European Journal of Neuroscience. 19 (8): 2212–2220.
doi:
10.1111/j.0953-816X.2004.03297.x.
PMID15090047.
S2CID19479968.
^Delevett P (9 January 2000).
"Cash is king, focus is queen". Silicon Valley Business Journal.
Archived from the original on 5 February 2017. Retrieved 5 February 2017.
^Morris H, Wallach J (July 2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Testing and Analysis. 6 (7–8): 614–632.
doi:
10.1002/dta.1620.
PMID24678061.
^Natter J, Michel B (September 2020). "Memantine misuse and social networks: A content analysis of Internet self-reports". Pharmacoepidemiology and Drug Safety. 29 (9): 1189–1193.
doi:
10.1002/pds.5070.
PMID32602152.
S2CID220270495.
Lipton SA (April 2005). "The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism". Current Alzheimer Research. 2 (2): 155–165.
doi:
10.2174/1567205053585846.
PMID15974913.